ReviewFrontiers in immunology2026
Th17 cells and IL-17A in traumatic brain injury: mechanisms and therapeutic perspectives.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) triggers a complex cascade of immune responses that extend beyond the central nervous system and contribute to secondary neuropathology. Increasing evidence implicates T helper 17 cells (Th17) and their signature cytokine interleukin-17A (IL-17A) in post-traumatic neuroinflammatory processes, including blood-brain barrier (BBB) disruption and neuroimmune interactions. This review synthesizes current evidence on the context-dependent roles of Th17 cells and IL-17A in TBI, with a focus on underlying molecular mechanisms, cellular targets, and the limitations of existing experimental data. We further discuss emerging therapeutic strategies aimed at modulating the Th17/IL-17A axis, as well as recent observations linking IL-17A signaling to neural plasticity and functional outcomes. Taken together, these findings highlight both the translational challenges and conceptual opportunities associated with targeting Th17/IL-17A-related pathways following TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.